1. Myeloid CD11c+ S100+ dendritic cells express indoleamine 2,3-dioxygenase at the inflammatory border to invasive lower lip squamous cell carcinoma.
- Author
-
Kuales MA, Wenzel J, Schmid-Wendtner MH, Bieber T, and von Bubnoff D
- Subjects
- Aged, Aged, 80 and over, Biomarkers, Tumor metabolism, Bone Marrow Cells metabolism, CD11c Antigen metabolism, Carcinoma, Squamous Cell enzymology, Dendritic Cells enzymology, Female, Humans, Lip Neoplasms enzymology, Male, Middle Aged, Neoplasm Staging, S100 Proteins metabolism, Tumor Escape physiology, Bone Marrow Cells pathology, Carcinoma, Squamous Cell pathology, Dendritic Cells pathology, Indoleamine-Pyrrole 2,3,-Dioxygenase metabolism, Lip Neoplasms pathology
- Abstract
The prevalence of squamous cell carcinoma of the lower lip (SCC-LL) is increasing worlwide. The expression of the enzyme indoleamine 2,3-dioxygenase (IDO) by antigen-presenting cells and/or tumor cells leads to tumor escape by inhibiting T cell-mediated rejection responses. The aim of this study was to determine the expression of IDO in SCC-LL. IDO-expression was analyzed in 47 SCC-LL, together with the expression of markers of T-cells (CD3), myeloid DCs (S100, CD11c), macrophages (CD68, CD11c), Langerhans cells (CD1a, Langerin (CD207)), plasmacytoid DCs (CD123), and regulatory T cells (Foxp3) by immunohistochemistry and immunofluorescence analysis. Twelve specimens out of 47 LL-SCCs contained cells that expressed IDO. IDO-positivity was strongly associated with the intensity of the cancer-associated infiltrate (P=0.0007). IDO-positive cells are located right along the border between the developing tumor and the inflammatory infiltrate. Immunofluorescence stainings showed that CD11c+S100+CD68- dendritic cells (DCs) express IDO in SCC-LL. IDO expression in LL-SCC may aid immune escape and chronic inflammation to promote cancer progression. Inhibition of IDO might be a therapeutic strategy to increase the anti-tumor immune response in SCC-LL.
- Published
- 2011
- Full Text
- View/download PDF